{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T17:02:57Z","timestamp":1795280577662,"version":"4.10.3"},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2023,1,1]]},"abstract":"<jats:sec id=\"ab-eoi220072-4\"><jats:title>Importance<\/jats:title><jats:p>The association of proliferative diabetic retinopathy (PDR) interventions of panretinal photocoagulation (PRP) and intravitreal injections (IVIs) with tractional retinal detachment (TRD) is unclear.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220072-5\"><jats:title>Objectives<\/jats:title><jats:p>To determine whether different treatment types or a 6-month or longer period of loss to follow-up (LTFU) is associated with TRD.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220072-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This nested case-control study included data from January 1, 2000, to June 30, 2021, of patients with PDR. Those who progressed to TRD were matched to non-TRD controls up to a 5:1 ratio. Exclusion criteria included 2 or fewer years in the plan, history of nondiabetic retinopathy, vitreous hemorrhage, previous RD, or any other surgically indicated diagnosis.  Patient data were obtained from a deidentified commercial and Medicare Advantage medical claims database. Statistical analysis was performed from January to May 2022.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220072-7\"><jats:title>Exposures<\/jats:title><jats:p>Primary exposures of interest were prior treatment (PRP, IVI, both) and any period of 6 months or longer in which the patient received no eye care.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220072-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Odds ratios (ORs) of IVI only compared with PRP and 6-month or longer LTFU on development of TRD.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220072-9\"><jats:title>Results<\/jats:title><jats:p>After application of inclusion and exclusion criteria, a total of 214 patients (mean [SD] age, 55.6 [12.4] years; 115 female [53.7%]) with PDR and TRD were matched to 978 controls (mean [SD] age, 65.6 [11.3] years; 507 female [51.8%]) with only PDR. Among patients with TRD, 69 (32.2%) were treated with laser only, 17 (7.9%) were treated with injection only, 39 (18.2%) were treated with both, and 89 (41.6%) had no prior treatment. Among patients in the PDR-only group, 207 (21.2%) received laser only, 83 (8.5%) received injection only, 57 (5.8%) received both, and 631 (64.5%) received no treatment. After adjusted analysis, no difference in odds of TRD for patients who received injection only compared with patients who received laser only was found (adjusted OR [aOR],\u20090.56; 95% CI, 0.27-1.14). Patients who received both treatments had higher odds of TRD compared with those who received laser only (aOR,\u20092.33; 95% CI, 1.21-4.48), and patients who had no treatment had lower odds of TRD (aOR,\u20090.46; 95% CI, 0.29-0.71; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001 for treatment category). Similarly, no difference was seen in the odds of TRD between those with LTFU for 6 months or longer and those without LTFU (aOR,\u20090.72; 95% CI, 0.49-1.07; <jats:italic>P<\/jats:italic>\u2009= .11).<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220072-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Results of this case-control analysis suggest that there is no increased risk of TRD associated with IVI-only treatment or with 6-month or longer periods of LTFU, which supports the findings of other investigations. Nonetheless, LTFU rates continue to remain high in patients with PDR, which can contribute to substantial vision loss regardless of treatment regimen.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2022.4942","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T16:32:06Z","timestamp":1669912326000},"page":"40","source":"Crossref","is-referenced-by-count":11,"title":["Association of Treatment Type and Loss to Follow-up With Tractional Retinal Detachment in Proliferative Diabetic Retinopathy"],"prefix":"10.1001","volume":"141","author":[{"given":"Jonathan C.","family":"Tsui","sequence":"first","affiliation":[{"name":"Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinxi","family":"Yu","sequence":"additional","affiliation":[{"name":"Center for Preventative Ophthalmology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"VanderBeek","sequence":"additional","affiliation":[{"name":"Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philadelphia"},{"name":"Center for Pharmacoepidemiology Research and Training, University of Pennsylvania Perelman School of Medicine, Philadelphia"},{"name":"Leonard Davis Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"eoi220072r1","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study.","volume":"9","author":"GBD 2019 Blindness and Vision Impairment Collaborators","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"12","key":"eoi220072r2","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.4103\/ijo.IJO_1217_18","article-title":"Current management of diabetic tractional retinal detachments.","volume":"66","author":"Stewart","year":"2018","journal-title":"Indian J Ophthalmol"},{"issue":"20","key":"eoi220072r3","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial.","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"issue":"10085","key":"eoi220072r4","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","article-title":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.","volume":"389","author":"Sivaprasad","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"eoi220072r5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ophtha.2019.09.025","article-title":"Diabetic Retinopathy Preferred Practice Pattern.","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi220072r6","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00417-020-04944-w","article-title":"Visit adherence and visual acuity outcomes in patients with diabetic macular edema: a secondary analysis of DRCRnet protocol T.","volume":"259","author":"Ramakrishnan","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"eoi220072r7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/jamaophthalmol.2019.4577","article-title":"Association of visit adherence and visual acuity in patients with neovascular age-related macular degeneration: secondary analysis of the comparison of Age-Related Macular Degeneration Treatment Trial.","volume":"138","author":"Ramakrishnan","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"eoi220072r8","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2018.02.034","article-title":"Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections.","volume":"125","author":"Obeid","year":"2018","journal-title":"Ophthalmology"},{"key":"eoi220072r9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ajo.2019.03.005","article-title":"Antivascular endothelial growth factor therapy for diabetic retinopathy: consequences of inadvertent treatment interruptions.","volume":"204","author":"Wubben","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"eoi220072r10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ophtha.2018.07.027","article-title":"Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation vs intravitreal antivascular endothelial growth factor.","volume":"126","author":"Obeid","year":"2019","journal-title":"Ophthalmology"},{"issue":"12","key":"eoi220072r11","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jamaophthalmol.2021.4103","article-title":"Lapses in care among patients assigned to ranibizumab for proliferative diabetic retinopathy: a post hoc analysis of a randomized clinical trial.","volume":"139","author":"Maguire","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"eoi220072r12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1097\/IAE.0000000000002633","article-title":"Antivascular endothelial growth factor therapy and risk of traction retinal detachment in eyes with proliferative diabetic retinopathy: pooled analysis of 5 DRCR retina network randomized clinical trials.","volume":"40","author":"Bressler","year":"2020","journal-title":"Retina"},{"issue":"1","key":"eoi220072r13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1001\/jamaophthalmol.2013.577","article-title":"Accuracy of International Classification of Diseases, 9th revision, clinical modification billing codes for common ophthalmic conditions.","volume":"131","author":"Muir","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"eoi220072r14","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaophthalmol.2017.1595","article-title":"Accuracy of billing codes used in the therapeutic care of diabetic retinopathy.","volume":"135","author":"Lau","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"eoi220072r15","first-page":"15","article-title":"Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization.","volume":"14","author":"Young","year":"2008","journal-title":"Am J Manag Care"},{"key":"eoi220072r16","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ajo.2017.01.010","article-title":"Intravitreal bevacizumab for the treatment of vitreous hemorrhage due to proliferative diabetic retinopathy.","volume":"176","author":"Parikh","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"eoi220072r17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ajo.2020.03.023","article-title":"Predictors of lost to follow-up in patients being treated for proliferative diabetic retinopathy.","volume":"216","author":"Green","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"eoi220072r18","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.ajo.2013.06.035","article-title":"Identification of persons with incident ocular diseases using health care claims databases.","volume":"156","author":"Stein","year":"2013","journal-title":"Am J Ophthalmol"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2799232\/jamaophthalmology_tsui_2022_oi_220072_1673287580.5669.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T16:23:24Z","timestamp":1674145404000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2799232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.4942","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,1]]}}}